| Literature DB >> 35616251 |
Jianfeng Shu1, Wei Ren2, Shu Chen3, Lin Li4, Hui Zhu5, Aixiang Jin5.
Abstract
BACKGROUND: This study was intended to evaluate the clinical effect of somatosensory interaction transcutaneous electrical acupoint stimulation (SI-TEAS) on cancer-related fatigue (CRF) and its safety.Entities:
Mesh:
Year: 2022 PMID: 35616251 PMCID: PMC9213073 DOI: 10.1097/COC.0000000000000922
Source DB: PubMed Journal: Am J Clin Oncol ISSN: 0277-3732 Impact factor: 2.787
FIGURE 1Overall structure of SI-TEAS Massage System. SI indicates somatosensory interaction.
FIGURE 2The Consolidated Standards for Reporting Trials (CONSORT) diagram.
The Comparison on the Characteristics of Participants
| Item | SI-TEAS Group (n=94), n (%) | Acupressure Group (n=92), n (%) | Sham Acupressure Group (n=93), n (%) |
|
|---|---|---|---|---|
| Sex | 0.461 | |||
| Male | 42 (44.68) | 49 (53.26) | 48 (51.61) | |
| Female | 52 (55.32) | 43 (47.74) | 45 (48.39) | |
| Age (mean±SD) (y) | 47.46±6.42 | 46.72±7.52 | 47.40±6.56 | 0.717 |
| Marriage | 0.215 | |||
| Single | 5 (5.32) | 11 (11.96) | 4 (4.30) | |
| Married | 81 (86.17) | 72 (78.26) | 83 (89.25) | |
| Divorced/widowed | 8 (8.51) | 9 (9.78) | 6 (6.45) | |
| Education | 0.061 | |||
| Senior high school and below | 45 (47.87) | 33 (35.87) | 49 (52.69) | |
| College and above | 49 (52.13) | 59 (64.13) | 44 (47.31) | |
| Tumor type | 0.094 | |||
| Head and neck cancer | 9 (9.57) | 13 (14.13) | 15 (16.13) | |
| Breast cancer | 24 (25.53) | 10 (10.87) | 29 (31.18) | |
| Lung cancer | 11 (11.70) | 19 (20.65) | 8 (8.60) | |
| Liver cancer | 12 (12.77) | 14 (15.22) | 13 (13.98) | |
| Gastric cancer | 12 (12.77) | 13 (14.13) | 7 (7.53) | |
| Intestinal cancer | 13 (13.83) | 11 (11.96) | 8 (8.60) | |
| Cervical cancer | 9 (9.57) | 6 (6.52) | 10 (10.75) | |
| Others | 4 (4.26) | 6 (6.52) | 3 (3.23) | |
| TNM Staging | 0.348 | |||
| Stage I | 18 (19.15) | 18 (19.57) | 9 (9.68) | |
| Stage II | 31 (32.98) | 36 (39.13) | 36 (38.71) | |
| Stage III | 32 (34.04) | 31 (33.70) | 38 (40.86) | |
| Stage IV | 13 (13.83) | 7 (7.61) | 10 (10.75) | |
| Treatment method | ||||
| Surgery | 71 (75.53) | 76 (82.61) | 81 (87.10) | 0.119 |
| Chemotherapy | 61 (64.89) | 63 (68.48) | 67 (72.04) | 0.575 |
| Radiotherapy | 28 (29.79) | 32 (34.78) | 43 (46.24) | 0.058 |
| Immunity | 20 (21.28) | 19 (20.65) | 21 (22.58) | 0.948 |
| Targeted | 5 (5.32) | 5 (5.43) | 7 (7.53) | 0.778 |
| Others | 21 (22.34) | 16 (17.39) | 23 (24.73) | 0.464 |
SI-TEAS indicates somatosensory interaction transcutaneous electrical acupoint stimulation; TNM, tumor, node, metastases.
Intergroup Comparison in Different Fatigue Dimensions and Immunity at Different Time Points
| Baseline Visit | Week 4 Visit | Week 8 Visit | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Mean (SD) | |||||||||
| Variable | SI-TEAS Group (n=94) | Acupressure Group (n=92) | Sham Acupressure Group(n=93) | SI-TEAS Group (n=94) | Acupressure Group (n=92) | Sham Acupressure Group (n=93) | 95% CI | SI-TEAS Group (n=94) | Acupressure Group (n=92) | Sham Acupressure Group (n=93) | 95% CI |
| RPFS | |||||||||||
| Behavioral | 6.61 (0.81) | 6.79 (1.33) | 6.92 (1.04) | 5.21 (0.78) | 5.76 (1.36) | 6.89 (1.03) | (−0.86,−0.24) | 3.59 (0.77) | 4.59 (1.35) | 6.93 (1.05) | (−1.31,−0.69) |
| Sensory | 6.99 (0.69) | 6.74 (1.31) | 6.70 (1.13) | 4.92 (0.75) | 6.28 (1.34) | 6.63 (1.14) | (−1.68,−1.04) | 2.81 (0.70) | 5.20 (1.41) | 6.65 (1.14) | (−2.72,−2.08) |
| Emotional | 6.76 (1.21) | 6.73 (0.86) | 7.02 (1.10) | 4.91 (1.18) | 5.70 (0.90) | 6.96 (1.16) | (−1.07,−0.44) | 2.80 (1.18) | 4.36 (0.92) | 6.97 (1.12) | (−1.87,−1.25) |
| Cognitive | 6.88 (1.20) | 6.72 (1.21) | 6.80 (1.09) | 4.88 (1.16) | 5.70 (1.24) | 6.76 (1.13) | (−1.17,−0.49) | 2.75 (1.13) | 4.39 (1.29) | 6.73 (1.16) | (−1.98,−1.29) |
| Total score | 6.83 (0.60) | 6.76 (0.56) | 6.87 (0.59) | 4.99 (0.58) | 5.87 (0.56) | 6.82 (0.58) | (−1.04,−0.71) | 3.00 (0.58) | 4.64 (0.54) | 6.83 (0.58) | (−1.80,−1.48) |
| Lymphocyte subsets | |||||||||||
| CD3+ | 840.97 (135.18) | 847.01 (119.47) | 817.72 (126.45) | 1137.62 (98.59) | 1000.69 (117.98) | 821.33 (134.55) | (102.90,170.97) | 1347.29 (58.17) | 1187.51 (62.84) | 829.25 (118.34) | (135.43,184.12) |
| CD4+ | 512.04 (56.93) | 521.39 (60.87) | 505.09 (65.39) | 685.73 (61.10) | 613.82 (67.45) | 509.27 (71.04) | (52.68,91.16) | 882.38 (58.98) | 722.70 (58.86) | 503.12 (61.11) | (142.46,176.91) |
| CD8+ | 332.57 (30.53) | 336.38 (29.57) | 330.17 (32.21) | 421.09 (32.23) | 382.75 (31.77) | 333.12 (35.00) | (28.80,47.87) | 521.27 (30.68) | 440.52 (31.28) | 329.82 (31.16) | (71.78,89.71) |
| CD4+/CD8+ | 1.54 (0.07) | 1.55 (0.08) | 1.53 (0.07) | 1.63 (0.03) | 1.60 (0.06) | 1.52 (0.09) | (0.01,0.05) | 1.69 (0.04) | 1.64 (0.03) | 1.52 (0.06) | (0.04,0.07) |
| NK | 282.69 (30.74) | 286.75 (29.82) | 280.23 (32.39) | 372.94 (32.03) | 338.03 (38.38) | 283.63 (37.25) | (24.72,45.09) | 487.47 (32.25) | 400.30 (54.12) | 279.65 (31.22) | (75.47,98.86) |
Derived from a linear mixed model.
SI-TEAS Group versus Acupressure Group.
Acupressure Group versus Sham Acupressure Group.
SI-TEAS Group versus Sham Acupressure Group.
RPFS indicates Revised Piper Fatigue Scale; SI-TEAS, somatosensory interaction transcutaneous electrical acupoint stimulation.
FIGURE 3Comparison of cancer-related fatigue patients in the 3 groups in piper score during the baseline period and after 4 and 8 weeks of intervention.
FIGURE 4Comparison of cancer-related fatigue patients in the 3 groups in the absolute counts of lymphocyte subsets during the baseline period and after 4 and 8 weeks of intervention.